

Contents

Abscess, Brain	1
Abscess, Epidural	4
Acalculia	5
Acid-Base Disturbances	5
ADEM Disease	7
Agnosia	8
Agraphia	10
AIDS	11
Alcohol	16
Alexia	19
Amaurosis Fugax	20
Aneurysmal Subarachnoid Hemorrhage	22
Angelman Syndrome	24
Angiography	24
Angiomas	25
Antibody Testing in Neuromuscular Disease	29
Antidepressants	35
Aphasia	37
Apraxia	40
Arteriovenous Malformations	42
Asterixis	44
Ataxia, Spinocerebellar Degeneration	45
Athetosis (See Also Chorea)	48
Attention-Deficit Hyperactivity Disorder	49
Autism	54
Autonomic Dysfunction	57
Balint Syndrome	62
Benzodiazepines	62
Bladder	63
Botulinum Toxin	66
Brachial Plexus	67
Brain Death	69
Bulbar Palsy	71
Cadasil	73
Caloric Testing	74
Cardiopulmonary Arrest (See also Brain Death, COMA)	75
Carotid-Cavernous Fistula	76
Carotid Stenosis (See also Ischemia)	77
Carpal Tunnel Syndrome	78
Catamenial Epilepsy	81
Cauda Equina and Conus Medullaris	83
Cerebellum	83
Cerebral Aneurysms	86

Cerebral Cortex	87
Cerebral Hemorrhage, Intracranial Hemorrhage, Subarachnoid Hemorrhage	89
Cerebral Palsy	94
Cerebral Salt-Wasting Syndrome	95
Cerebrospinal Fluid	96
Channelopathies	100
Chemotherapy, Neurologic Complications	105
Chiari Malformations	107
Child Neurology: History, and Physical Examination	108
Chorea	116
Chromosomal Disorders	118
COMA (See also Brain Death, Cardiopulmonary Arrest, and AAN Guideline Appendix)	121
Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy)	128
Computed Tomography	130
Conversion Disorder	133
Confusional State (See Delirium)	134
Cramps	134
Cranial Nerves	140
Craniocervical Junction (See also Arnold-Chiari Malformation)	144
Craniosynostosis	144
Creutzfeldt-Jakob Disease; Other Human Prion Diseases	146
Degenerative Diseases of Childhood	149
Dementia (See also AAN Guideline Summaries Appendix)	153
Delirium (Acute confusional state)	164
Demyelinating Disorders	166
Dermatomes	169
Diabetes Insipidus	171
Dialysis (Central Nervous System Complications)	172
Disseminated Intravascular Coagulation	173
Dizziness	174
Dysarthria	175
Dyskinesia; Tardive (See also Therapeutic Appendix)	176
Dysphagia	177
Dystonia	181
Electrocardiogram and Cardiac Effects of Neurological Disorders	183
Electroencephalography	183
Electrolyte Disorders	187
Electromyography and Nerve Conduction Studies	192
Embryology of the Congenital Malformations of the Brain and Spine	198
Encephalitis	200
Encephalopathy	205

Encephalopathy, Perinatal Hypoxic-Ischemic	205
Endovascular Treatment of Aneurysms	207
Epilepsy and Women (See also Catamenial Epilepsy, Epilepsy, and AAN Guideline Summaries Appendix)	208
Epilepsy (See also AAN Guideline Summaries, Neurologic Emergency, and Therapeutic Appendices)	210
Erectile Dysfunction; Impotence	225
Evoked Potentials	227
Extracranial Ultrasonography	232
Eye Muscles	233
Facial Nerve, Hemifacial Spasm	235
Femoral Nerve	240
Fontanel	242
Fragile X Syndrome	242
Frontal Lobe	243
Frontal Lobe Lesions and Syndromes	244
Frontal Lobe Seizure	244
Functional Magnetic Resonance Imaging	244
Gait Disorders	246
Gaze Palsy	248
Gerstmann Syndrome	249
Glossopharyngeal Neuralgia	249
Glucose Imbalance	250
Graves Ophthalmopathy	252
Guillain-Barré Syndrome (See also Neuropathy)	253
Hallucinations	257
Head Trauma	258
Headache: Migraine and Other Types (See also AAN Guideline Summaries Appendix)	259
Hearing	270
Hemifacial Spasm	271
Herniation	272
Hiccups (Singultus, Hiccoughs)	274
Horner Syndrome, Cocaine Test	276
Huntington Disease	278
Hydrocephalus	280
Hyperventilation	282
Hypotonic Infant/Hypotonia in Infancy/Floppy Infant	283
Idiopathic Intracranial Hypertension	288
Immunization, Vaccination	289
Intracranial Pressure	291
Intracranial Stenosis	294
Ischemia (Stroke and Transient Ischemic Attack) (See also The Neurologic Emergency Appendix, Acute Ischemic Stroke)	295
Lambert-Eaton Myasthenic Syndrome	313

Learning Disabilities	314
Limbic System	315
Lumbosacral Plexopathy	316
Lyme Disease, Neuroborreliosis	318
Macrocephaly	321
Magnetic Resonance Imaging	323
Magnetoencephalography	328
Marburg Disease	329
Mechanical Thrombectomy for Acute Ischemic Stroke (See Thrombectomy)	330
Melas	331
Memory	332
Meningitis (See also Neurologic Emergency Appendix)	334
Mental Status Testing	339
Metabolic Diseases of Childhood	339
Microcephaly	343
Mitochondrial Disorders	344
Motor Neuron Disease, Amyotrophic Lateral Sclerosis (See also AAN Guideline Summaries Appendix)	346
Moyamoya Disease	350
Multiple Sclerosis (See also AAN Guideline Summaries and Therapeutic Appendices)	352
Muscle Diseases and Testing	357
Muscular Dystrophy	361
Myasthenia Gravis	368
Myelography	371
Myoclonus	372
Myoglobinuria, Rhabdomyolysis, Creatine Kinase	375
Myopathy	379
Myotomes	386
Myotonia, Myotonic Dystrophy	389
Neglect	393
Neurocutaneous Syndromes	393
Neuroleptic Malignant Syndrome	397
Neuroleptics	399
Neuropathy (See also AAN Guideline Summaries Appendix)	404
Nutritional Deficiency Syndromes	413
Nystagmus	413
Occipital Lobe	423
Ocular Oscillations	423
Olfaction	424
Opalski Syndrome	426
Ophthalmoplegia	426
Optic Nerve	430
Optokinetic Nystagmus	433

Paget Disease	435
Pain	436
Paraneoplastic Neurologic Syndromes	440
Parietal Lobe	442
Parkinson Disease	443
Parkinsonism	451
Periodic Paralysis (See Myotonia)	454
Peripheral Nerve Disease (See also Neuropathy)	456
PET and SPECT	458
Pituitary Disorders (Pituitary Adenoma, Hypo- and Hyperpituitarism, Apoplexy)	467
Porphyria	471
Posterior Reversible Encephalopathy Syndrome (PRES), See also Hypertensive Encephalopathy	475
Pregnancy	475
Progressive Supranuclear Palsy	481
Pseudobulbar Palsy	483
Pseudotumor Cerebri	484
Ptosis	485
Pupil	486
Radial Nerve	492
Radiation Injury	494
Radiculopathy	497
Reflexes	501
Respiratory Failure	502
Restless Legs Syndrome (Willis-ekbom Syndrome)	505
Retina and Uveal Tract (Uveitis)	506
Reversible Cerebral Vasoconstriction Syndrome, Call-fleming Syndrome	508
Rheumatoid Arthritis	511
Rigidity	512
Romberg Sign	514
Sarcoidosis	515
Sciatic Nerve, Sciatica	517
Sepsis	519
Shunts, Third Ventriculostomy, Ventriculoperitoneal Shunts	520
Sickle Cell Disease	522
Sleep Disorders	525
Spasticity	529
Spinal Cord	530
Spinal Cord Compression (See also Spinal Cord Trauma, Spinal Cord Injury In Neurologic Emergency Appendix)	535
Spinal Cord Trauma (See also Spinal Cord Compression and Neurologic Emergencies Appendix)	539

Spinal Cord Infarction	539
Spinal Epidural Abscesses	541
Spinocerebellar Ataxia (See also Ataxia)	542
Spinocerebellar Degeneration (Spinocerebellar Ataxia)	543
Status Epilepticus (See also Epilepsy NCC and Neurologic Emergencies Appendix)	544
Subdural Hematoma	545
Syncope	547
Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH)	549
Syphilis	550
Taste	552
Tauopathies	553
Temporal Lobe	555
Thyroid	556
Thrombectomy for Acute Ischemic Stroke	558
Tourette Syndrome (Gilles De La Tourette Syndrome)	560
Transcranial Doppler Ultrasound	562
Transplantation	563
Tremors (See also Therapeutic Appendix)	567
Trigeminal Neuralgia	569
Trinucleotide Repeat Expansion	571
Tumor Embolization	573
Tumors	573
Ulnar Nerve (See also Peripheral Nerve)	580
Ultrasonography (See Transcranial Doppler)	581
Uremia	582
Vasculitis	584
Vein of Galen Malformation	589
Venous Thrombosis	590
Vertebroplasty/kyphoplasty	592
Vertigo	593
Vestibulo-Ocular Reflex	597
Visual Fields	598
Wada Testing	600
White Matter Tract Lesion in Multiple Sclerosis—Radiographic Features	600
Wilson Disease	601
Zoster	603
AAN Guideline summaries appendix	606
Evaluation and Prognosis of Coma	606
Diagnostic Accuracy of 14-3-3 Protein in Sporadic Creutzfeldt-Jakob Disease	607
Diagnosis and Management of Dementia	608
Child neurology: Summary of all guidelines	612

Concussion: Evaluation and Management of Concussion in Sport	614
Women With Epilepsy	615
New Anti-Epileptic Drugs (AED) in the Treatment of Newly Diagnosed Epilepsy	617
New Anti-Epileptic Drugs (AED) in the Treatment of Refractory Epilepsy	620
Patent Foramen Ovale and Stroke	622
Diagnosis of Patients With Neuroborreliosis	624
Migraine Diagnosis and General Treatment Consideration	625
Acute and Preventive Therapy of Migraine Headache in Children and Adolescents	633
Supportive Management of Amyotrophic Lateral Sclerosis	633
Algorithms for Nutritional and Respiratory Management of ALS	636
Magnetic Resonance Imaging (MRI) in Multiple Sclerosis (MS) and Diagnostic Consideration in Patients With White Matter Lesions	638
Disease-Modifying Therapies in Multiple Sclerosis	640
Surgical Therapy of Diabetic Neuropathy	644
Immunotherapy in Management of Guillain-Barré Syndrome	645
Treating Parkinson Disease	646
Treating Behavioral Changes in Parkinson Disease	648
Standards of Transcranial Doppler Application	649
Strokes Guidelines Summary	652
Neurologic Emergency Appendix	658
Acute Ischemic Stroke	658
Bacterial Meningitis and Severe Encephalitis	659
Myasthenic Crisis	660
Headache Management	662
Hemorrhagic Stroke, Intracranial Hemorrhage, Subarachnoid Hemorrhage, See Stroke	664
Intracranial Pressure Management	667
Intoxication, Alcohol, and Illicit Drugs	669
Neuromuscular Diseases	674
Neuropathic Pain	674
Nonacute Ischemic Stroke	676
Quadriplegia	677
Spinal Cord Injury	680
Status Epilepticus, Seizure	681
Traumatic Brain Injury (TBI)	684
Therapeutic Appendix	686
Chemotherapy: common Neuro-Oncologic drugs	686
Chorea (Movement Disorder)	689
Dementia: Primary Medications	691
Depression	693
Epilepsy	696

Treatment For Essential Tremor (Movement Disorder)	701
Headache	703
Insomnia	704
Multiple sclerosis	707
Myasthenia Gravis	713
Narcolepsy	717
Neuro-Oncology, Therapeutics	719
Obstructive Sleep Apnea-Hypopnea Syndrome	720
Paget Disease	723
Pain (See also Headache, AED, and Antidepressants in AAN Guideline Summaries Appendix)	725
Parkinson Disease (Movement Disorder)	730
Restless Legs Syndrome	731
Sedatives and Paralytics	732
Spasticity (Movement Disorder)	735
Stroke	736
TICS (Movement Disorder)	740
Scales Appendix	741
Chalfont Seizure Severity Scale	741
Epworth Sleepiness Scale	742
Fisher Scale	743
Glasgow Coma Scale	743
Glasgow Outcome Rating Scale	744
Hunt and Hess Clinical Severity Scale for Subarachnoid Hemorrhage	744
Kurtzke Expanded Disability Status Scale (EDSS)	744
Kurtzke Functional Systems Scores (FSS)	745
Mini-Mental State Examination (MMSE)	747
Modified Rankin Clinical Disability Scale	749
NIH Stroke Severity Scale (NIHSS)	749
Parkinson Disease Rating Scales	752
Spetzler-Martin Scale for Arteriovenous Malformation	759
Index	760

A

ABSCCESS, BRAIN

Brain abscess is a focal pyogenic infection of the brain parenchyma. They constitute less than 2% of intracranial masses and develop mainly in four clinical situations, although 15% to 20% are cryptogenic.

- I. *Contiguous spread* (45%–50% of all cases) via direct extension from local neighboring infection sites—frontal or ethmoid sinusitis or dental infection (frontal lobe abscess), middle ear or mastoid air cell infection (temporal lobe and cerebellar abscess), spread by local osteomyelitis or by septic thrombophlebitis of emissary vein.
- II. *Hematogenous spread* from distant sites of infection (25%), usually multiple and multiloculated, often in the middle cerebral artery distribution. Common sources of metastatic brain abscesses are pulmonary or abdominopelvic infections, cyanotic heart disease, congenital heart malformations with right-to-left shunts (oral bacterial flora after dental procedures), or bacterial endocarditis.
- III. *Trauma* including penetrating head injury or neurosurgical procedures (10%)—compound depressed skull fractures, basal skull fractures with cerebrospinal fluid (CSF) fistulae/leak, and previous craniotomy can lead to brain abscess, sometimes months or years after the acute event. Postneurosurgic abscesses may occur, especially when surgery involves paranasal air sinuses.
- IV. *Immunosuppression*. People with acquired immune deficiency syndrome (AIDS) or with other causes of immunosuppression (e.g., neoplasms, steroid use) are susceptible to bacterial infections or infections associated with decreased T-cell immunity such as mycobacteria, fungi, or *Toxoplasmosis*.

Pathogens isolated from abscesses are related to the site of origin, as follows (organisms are listed in order of significance; many abscesses are polymicrobial):

- I. Middle ear infection: streptococci (aerobic and anaerobic), *Bacteroides fragilis*, and Enterobacteriaceae (Proteus).
- II. Sinusitis: same as middle ear infections, plus *Staphylococcus aureus*, *Haemophilus* species, and mucormycosis (also seen with orbital cellulitis).
- III. Penetrating head trauma: *S. aureus*, streptococci, Enterobacteriaceae, *Clostridium* species, and *Pseudomonas aeruginosa*.
- IV. AIDS/immunocompromised: *Toxoplasma*, *Mycobacterium*, *Listeria* species infection, *Listeria monocytogenes*, *Nocardia*, and *Cryptococcus neoformans*.

CLINICAL FEATURES

Clinical features usually resemble those of other space-occupying lesions (focal signs, seizures in 25%–35% of patients) with most symptoms related to

A

ABSCCESS, BRAIN

increased intracranial pressure (ICP) (headache, nausea, vomiting, lethargy, and stupor). Fever occurs in only 50% of cases.

HISTOPATHOLOGIC STAGES

Days 1 to 3: Early cerebritis produces a local inflammatory response (usually within white matter or at the gray-white matter junction) around a necrotic center.

Days 4 to 9: Late cerebritis is characterized by increased necrosis and inflammation, with initial fibroblastic formation of the collagen capsule.

Days 10 to 13: Early encapsulation stage shows further development of the collagen capsule, which is typically thinner on the less vascular ventricular side.

Days 14 and later: Late capsular stage shows five distinct histologic layers—the necrotic center, inflammatory cells and fibroblasts, collagen capsule, neovascular layer, and surrounding reactive gliosis and edema.

WORK-UP

- I. Blood cultures should be drawn (positive in 15% of cases) and empiric parenteral antibiotic therapy must be initiated before computed tomography (CT) scan or magnetic resonance imaging (MRI). Lumbar puncture may be considered if mass effect is not prominent. However, the diagnostic yield is low and the risk of herniation is greater with abscess than with other mass lesions.
- II. CT scans correlate well with the histopathologic stages. In the cerebritis stage, CT without contrast shows the necrotic center as a hypodensity. Ring enhancement begins in the later stages of cerebritis. In capsular stages the capsule becomes visible on CT without contrast as a faint hyperdense ring that produces ring-enhancing lesion with contrast, which is thinner on the ventricular side.
- III. MRI appearance is bright on diffusion-weighted images (DWIs): T_1 delineates the abscess capsule as hyperintense/isointense and hypointense center and surrounding edema; T_2 demonstrates the hyperintense edema and center and hypointense capsule, enhances with gadolinium.
- IV. MR spectroscopy (MRS) can differentiate between abscess, necrotizing tumor, or granuloma. The main finding of MRS in abscesses is elevation of metabolites of bacterial origin, including acetate, lactate, succinate, and amino acids versus necrotic brain tumors with elevated choline and decreased N-acetylaspartate (NAA). The MRS pattern may monitor effectiveness of medical treatment of a brain abscess, showing a decline of the metabolites after a positive response to therapy.
- V. Other studies include electroencephalogram (EEG) which may show nonspecific findings such as focal slowing, seizure activity, and evidence of

encephalopathy. Cerebral angiography may show avascular mass and luxury perfusion.

TREATMENT

A combination of broad-spectrum antimicrobials, management of raised ICP, neurosurgical drainage or excision, and eradication of the primary infectious focus is indicated. If CT shows only cerebritis or abscess less than 2.5 cm and the patient is neurologically stable, antibiotics without surgery may suffice. Neurologic deterioration usually mandates surgery.

Excision or aspiration is performed for abscesses greater than 2.5 cm in diameter. Aspiration has become the procedure of choice because it is equally effective and less invasive than excision. Empiric antibiotics should be given based on the expected etiologic agents, presumed route and source of infection, predisposing factors, and adjusted based on the cultures. When the cause is unknown, the patient should receive a third- or fourth-generation cephalosporin, for example, ceftazidime 2 g IV q 8 hr (or ceftriaxone 2 g IV q 12 hr) or penicillin (PCN) G 5 MU IV q 6 hr, and metronidazole 500 mg IV q 6 hr. For paranasal sinus sources, administer PCN and metronidazole. In treatment of posttraumatic cases, administer nafcillin 2 g IV q 2 hr (or vancomycin 1 g IV q 12 hr, if methicillin-resistant *S. aureus* is suspected) and a third-generation cephalosporin such as ceftazidime 2 g IV q 8 hr. Treatment should be given for 6 to 8 weeks, often followed by additional 2 to 6 months of oral therapy or until the resolution of neuroimaging findings. Three to 4 weeks may be adequate in patients treated with surgical drainage. In human immunodeficiency virus (HIV)-positive patients, coverage should be added for toxoplasmosis with pyrimethamine plus sulfadiazine or clindamycin. Mucormycosis is treated with amphotericin B. Antiepileptic drugs may be given for up to 3 months. Routine corticosteroid administration is controversial and should be used only when mental status is significantly depressed and substantial mass effect can be demonstrated on imaging, and therapy should be of short duration.

PROGNOSIS

Mortality rates range from 5% to 15%. Poor prognosis is associated with very young or old age; anaerobic pathogens; large, multiple, deep, cerebellar, or multiloculated abscesses; acute clinical presentation with stupor/coma; intraventricular or subarachnoid rupture; concomitant pulmonary infection or sepsis; and specific organisms (i.e., *Aspergillus* and *Pseudomonas* species, fungal). Long-term sequelae include cognitive deficits (developmental delay in children), seizures, and focal deficits.

REFERENCES

- Brook, I. (2017). Microbiology and treatment of brain abscess. *J Clin Neurosci*, 38, 8–12. <https://doi.org/10.1016/j.jocn.2016.12.035>.
- Brouwer, M. C., Tunkel, A. R., McKhann, G. M., et al. (2014). Brain abscess. *N Engl J Med*, 31, 447–456.

A

ABSCESS, BRAIN

ABSCCESS, EPIDURAL

EPIDEMIOLOGY

Spinal epidural abscess (SEA) is an uncommon condition with an estimated incidence of 0.2 to 2.0/10,000 hospital admissions and a peak incidence in the sixth and seventh decades of life. Conditions commonly associated with SEA include diabetes mellitus, intravenous drug misuse, chronic renal failure, alcoholism, and cancer.

ETIOLOGY

The majority of SEAs are thought to result from the hematogenous spread of bacteria usually from a cutaneous or mucosal source with spread to the posterior aspect of the spinal canal. Direct spread from an adjacent source is less common and typically presents within the anterior aspect of the canal. The most common causative organisms are *Staphylococcus aureus* (57%–73%), *Mycobacterium tuberculosis* (25%), other gram-positive cocci (10%), gram-negative organisms 18%, and anaerobes 2%.

CLINICAL FEATURES

The initial manifestations of SEA are often nonspecific and include fever and malaise. The classical diagnostic triad consists of fever, spinal pain, and neurologic deficits. However, over time, an untreated abscess may progress from focal back pain, to radicular pain, to neurologic deficits (motor weakness, sensory changes, and bladder or bowel dysfunction), and then paralysis. Once paralysis develops, it may quickly become irreversible. Thus urgent intervention may be required if progression of weakness or other neurologic findings are detected.

TREATMENT

Surgical decompression and drainage with systemic antibiotic therapy is the treatment of choice. Empirical antimicrobial must be started early and be delivered intravenously in high doses and immediately following the collection of two sets of blood cultures. Appropriate empiric parenteral regimens include: vancomycin (15–20 mg/kg IV every 8–12 hours. Trough levels should be drawn 30 minutes prior to the next dose) for empiric coverage of methicillin resistant *Staphylococcus aureus* (MRSA) plus either ceftriaxone (2 g IV q 12 hr) or cefepime (2 g IV q 8 hr) or ceftazidime (2 g IV q 8 hr). Treatment should be continued for at least 4 weeks but may be prolonged for 8 weeks or longer if vertebral osteomyelitis is suspected.

PROGNOSIS

Overall prognosis is poor; 5% die due to uncontrolled sepsis or other complications, irreversible paraplegia occurs in 4% to 22%, and residual motor weakness in 37%.

REFERENCES

- Arko, L., Quach, E., Nguyen, V., Chang, D., Sukul, V., & Kim, B. S. (2014). Medical and surgical management of spinal epidural abscess: a systematic review. *Neurosurg Focus*, 37(2), E4.
- Bond, A., & Manian, F. A. (2016). Spinal epidural abscess: a review with special emphasis on earlier diagnosis. *Biomed Res Int*, 2016, 1614328.

ACALCULIA

Acalculia refers to an acquired computational disability (as opposed to developmental dyscalculia which occurs in 5% of school-age children and is usually associated with dyslexia). The ability to perform mathematical calculations is complex as it requires not only an arithmetic brain center, but also intact attention, language processing, spatial orientation, memory, body knowledge, and executive function.

Acalculia may be classified as either primary or secondary. Primary acalculia (anarithmetia), an acquired isolated defect in comprehending numerical systems, is rare. Notable secondary types due to other cognitive defects are: aphasic, an inability to read or write numbers, usually occurring with left posterior parietal lesions; spatial, a mental misalignment of numbers usually due to right posterior hemispheric lesions; and frontal, due to impaired attention, perseveration, and executive dysfunction.

Acalculia can be part of Gerstmann syndrome (acalculia, agraphia, right-left disorientation, and finger agnosia) due to left angular gyrus lesions. Common causes of acalculia include epilepsy, metabolic or genetic disorders, focal lesions (e.g., stroke, tumor, trauma, or abscess), or commonly as part of a neurodegenerative disease (e.g., dementia). Rehabilitation is treatment of choice, with variable results. Spontaneous recovery is seen in many stroke and trauma patients.

REFERENCES

- Ardila, A., & Rosselli, M. (2002). Acalculia and dyscalculia. *Neuropsychol Rev*, 12(4), 179–231.
- Rapin, I. (2016). Dyscalculia and the calculating brain. *Pediatr Neurol*, 61, 11–20.

ACID-BASE DISTURBANCES**RESPIRATORY ALKALOSIS**

This condition is most frequently observed in patients with hepatic cirrhosis, bronchial asthma, salicylate intoxication, hypoxia, sepsis, pneumonia, and acute anxiety (hyperventilation syndrome). Acute respiratory alkalosis constricts cerebral arterioles and decreases cerebral blood flow. Confusion accompanied by a slow electroencephalogram (EEG) may develop. Symptoms of milder respiratory alkalosis include paresthesias, dizziness, cramps as a result of coexistent tetany, hyperreflexia, and muscle weakness. More severe alkalosis (pH 7.52–7.65) in patients with respiratory insufficiency and hypoxia may result in a symptom complex of hypotension, seizures, asterixis, myoclonus, and coma. Treatment is to correct the underlying cause.

RESPIRATORY ACIDOSIS

Acute respiratory acidosis is a condition of low pH and high CO₂ concentration, occurring as a result of impairment of the rate of alveolar ventilation. Causes of acute respiratory acidosis include sedative drugs, brainstem injury, neuromuscular disorders, chest injury, airway obstruction, and acute pulmonary disease. Lethargy and confusion occur as the PCO₂ rises above 55 mm Hg. Seizures, stupor, or coma may occur with levels greater than 70 mm Hg. The serum bicarbonate level is either normal or high, depending on how rapidly the respiratory failure developed. Neurologic manifestations resulting from cerebral vasodilation include headache, increased intracranial pressure, and papilledema. Hyperreflexia or hyporeflexia and myoclonus may also occur.

Chronic respiratory acidosis generally occurs in patients with chronic obstructive pulmonary disease (COPD), restrictive lung disease (e.g., severe kyphoscoliosis), or extreme obesity (Pickwickian syndrome). It is most often symptomatic with acute exacerbations of disease. Compensatory polycythemia often results from chronic hypercapnic states. Hypoventilation or Pickwickian syndrome may manifest as excessive daytime somnolence.

Therapy of respiratory acidosis involves ventilatory support and treating the underlying disorder. The possibility of sedative or narcotic drug ingestion must be suspected in otherwise healthy patients who suddenly develop acute respiratory depression.

METABOLIC ALKALOSIS

Metabolic alkalosis may result from either excessive ingestion of base or excessive loss of acid. Causes of hypokalemic metabolic alkalosis include Cushing syndrome, vomiting or gastric drainage, diuretic therapy, and primary aldosteronism. Neurologic manifestations include paresthesias, cramps (due to tetany), muscle weakness (due to associated hypokalemia), and hyporeflexia. Severe metabolic alkalosis produces a blunted, confused state rather than stupor or coma and may result in cardiac arrhythmias and severe compensatory hypoventilation.

Treatment depends on the underlying cause.

METABOLIC ACIDOSIS

Metabolic acidosis occurs when a decrease in plasma bicarbonate level lowers pH. Cardinal features are hyperventilation and, when severe, *Kussmaul* respirations. In chronic metabolic acidosis, hyperventilation may be difficult to detect on clinical examination. The most common causes of metabolic acidosis sufficient to produce coma and hyperpnea include uremia, diabetes, lactic acidosis, and ingestion of acidic poisons. Ketoacidosis occasionally develops in severe alcoholics after prolonged drinking episodes. In diabetics treated with oral hypoglycemic agents, lactic acidosis and diabetic ketoacidosis must be considered.

The presence of neurologic symptoms depends on various factors, including the type of systemic metabolic defect, whether the fall in systemic pH

affects the pH of the brain and cerebrospinal fluid (CSF), the rate at which acidosis develops, and the specific anion causing the metabolic disorder. All forms of metabolic acidosis produce hyperpnea as the first neurologic symptom. Other manifestations include lethargy, drowsiness, confusion, and mild, diffuse skeletal muscle hypertonus. Extensor plantar responses occur at a later stage. Stupor, coma, or seizures generally develop only preterminally. Because metabolic acidosis is a manifestation of a variety of different diseases, the treatment varies depending on the underlying process and on the acuteness and severity of the acidosis.

REFERENCE

Yee, A. H., & Rabinstein, A. A. (2010). Neurologic presentations of acid-base imbalance, electrolyte abnormalities, and endocrine emergencies. *Neurology Clinics*, 28(1), 1–16.

ADEM DISEASE

ACUTE DISSEMINATED ENCEPHALOMYELITIS

Acute disseminated encephalomyelitis (ADEM) is a monophasic multifocal demyelinating disorder of the CNS, often following infection or vaccination. ADEM is more frequent in children; however, it may occur at any age. The most frequent preceding infections are flulike illnesses, nonspecific upper respiratory tract infections, and gastroenteritis. Although viral etiologies are most common, it can also follow a bacterial infections and, in rare cases, parasitic infections. Postvaccination ADEM is seen in approximately 10% of cases and is most common after measles, mumps, and rubella.

CLINICAL PRESENTATION

Initial presentation may include meningoencephalitis, fever, encephalopathy, seizures, headache, and meningismus. Focal motor or sensory deficits, ataxia, cranial neuropathies, or brain stem pathology may also be seen.

A more severe presentation known as acute hemorrhagic encephalomyelitis may develop.

DIAGNOSIS

MRI

MRI shows multifocal demyelinating lesions in CNS white matter, with increased signal in T2-weighted and FLAIR images. Lesions may be large, with poorly defined margins, and are often asymmetric. Lesions may enhance with contrast depending on the time of onset. Lesions that are hypointense on T1 argue against the diagnosis.

CSF

Lymphocytic pleocytosis and elevated protein are commonly seen; however, CSF studies can be normal.

A

ADEM DISEASE